FDA Advisory Committee Reviewed Imfinzi For Resectable Non-Small Cell Lung Cancer Based On Phase III Trial Results; AstraZeneca Reports Imfinzi Met Primary Endpoint Of Event-Free Survival And Was Generally Well Tolerated With No New Safety Signals
Portfolio Pulse from Benzinga Newsdesk
The FDA Advisory Committee reviewed AstraZeneca's Imfinzi for resectable non-small cell lung cancer based on Phase III trial results. AstraZeneca reported that Imfinzi met its primary endpoint of event-free survival and was generally well tolerated with no new safety signals.
July 25, 2024 | 7:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Imfinzi for resectable non-small cell lung cancer met its primary endpoint of event-free survival in a Phase III trial and was generally well tolerated with no new safety signals, according to the FDA Advisory Committee review.
The positive Phase III trial results for Imfinzi, including meeting the primary endpoint and showing no new safety signals, are likely to boost investor confidence in AstraZeneca. This could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100